Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 314
- Registration Number
- NCT02708095
- Locations
- πΊπΈ
The Ohio State University, Columbus, Ohio, United States
πΊπΈUniversity of Arizona, Tucson, Arizona, United States
π¨π³For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02703337
- Locations
- π©πͺ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02703324
- Locations
- π©πͺ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02703350
- Locations
- π©πͺ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
- Conditions
- Spondyloarthritis
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 341
- Registration Number
- NCT02696785
- Locations
- πΊπΈ
Klein and Associates MD, PA, Hagerstown, Maryland, United States
πΊπΈMarietta Rheumatology, Marietta, Georgia, United States
πΊπΈSarasota Arthritis Center, Sarasota, Florida, United States
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 316
- Registration Number
- NCT02696798
- Locations
- πΊπΈ
Rheumatology Center of San Diego, Escondido, California, United States
πΊπΈCare Access Research - Huntington Beach, Huntington Beach, California, United States
πΊπΈArthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC, Colorado Springs, Colorado, United States
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02688088
- Locations
- πΊπΈ
University of Kansas Hospital, Fairway, Kansas, United States
πΊπΈSouth Texas Accelerated Research Therapeutics, LCC, San Antonio, Texas, United States
πΊπΈSarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT02677116
- Locations
- πΊπΈ
St Jude Childrens Research Hospital, Memphis, Tennessee, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈChildrens Hospital of Los Angeles, Los Angeles, California, United States
A Study of Abemaciclib in Healthy Participants
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT02677844
- Locations
- πΊπΈ
Covance Clinical Research Unit, Evansville, Indiana, United States
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
- Conditions
- HER-2 Positive Breast CancerHormone Receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 237
- Registration Number
- NCT02675231
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈNorthwest Medical Specialties, PLLC, Puyallup, Washington, United States
πΊπΈComprehensive Blood and Cancer Center, Bakersfield, California, United States